Announcement • May 19
Clearmind Medicine Announces 1-For-10 Reverse Share Split to Regain Compliance with the Nasdaq Minimum Bid Price Rule Clearmind Medicine Inc. (“Clearmind” or the “Company”) announced that it will conduct a reverse share split of its issued and outstanding common shares, no par value, at a ratio of 1-for-10. The reverse split is being effected as part of the Company’s plan to regain compliance with the Nasdaq Minimum Bid Price Rule and will be effective commencing May 21, 2026. The reverse share split was approved by the Company’ board of directors on March 18, 2026, in accordance with the Company’s articles of association. Announcement • May 13
Clearmind Medicine Inc. Reaches Clinical Milestone In Phase I/IIa Trial Of CMND-100 For Alcohol Use Disorder Clearmind Medicine Inc. announced that two additional participants have been successfully dosed in the fourth cohort of its FDA-approved Phase I/IIa clinical trial evaluating CMND-100 (MEAI) for the treatment of moderate to severe Alcohol Use Disorder (AUD). This milestone brings the total number of participants treated to date across all cohorts to 20, reflecting strong momentum and continued progress in the multinational, multicenter study. The two newly dosed patients in the fourth cohort were treated at Hadassah-University Medical Center in Jerusalem, Israel, one of the key active trial sites. The fourth cohort features a higher dose of CMND-100 (160 mg), following the positive Data and Safety Monitoring Board (DSMB) recommendation and successful completion of the third cohort in April 2026. Building on highly encouraging safety and tolerability data from the first three cohorts (which included 18 participants and met the primary safety endpoint with no serious adverse events reported), the Company continues to advance the dose-escalation phase of the trial. Previous cohorts demonstrated a favorable safety profile consistent with earlier results, supporting further evaluation of CMND-100’s potential as a novel, non-hallucinogenic treatment option for AUD. The ongoing FDA-approved Phase I/IIa trial is a multinational, multicenter study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of CMND-100 in patients with moderate to severe AUD. The trial is being conducted at institutions including Yale School of Medicine, Johns Hopkins University School of Medicine, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center. Announcement • May 07
Clearmind Medicine Inc Announces Filing Of European Patent Application For Novel Psychedelic Compounds For Treatment Of PTSD Clearmind Medicine Inc. announced the filing of a European patent application for innovative psychedelic compounds targeting the treatment of Post-Traumatic Stress Disorder (PTSD) and other mental health disorders. The European patent application forms part of the Company’s exclusive worldwide licensing agreement with Yissum Research Development Company of the Hebrew University of Jerusalem. Under the terms of the licensing agreement, Clearmind holds exclusive global rights to develop, manufacture, and commercialize novel compounds developed at Yissum. The Company is responsible for advancing the development program in accordance with regulatory requirements. According to recent market reports, the global post-traumatic stress disorder (PTSD) treatment market is valued at approximately USD 18.5 billion in 2025 and is projected to reach USD 30.2 billion by 2035, growing at a CAGR of 5.0%. This filing further strengthens Clearmind’s robust intellectual property position in Europe, one of the world’s largest pharmaceutical markets. The move is particularly timely and significant in light of President Donald J. Trump’s Executive Order signed on April 18, 2026, which directs federal agencies to accelerate research, development, and regulatory review of psychedelic-based therapies for serious mental health conditions, including PTSD and substance use disorders. The order reflects a strong positive momentum and supportive policy environment for the advancement of innovative treatments in this field, especially for veterans and patients with unmet medical needs. The Company’s intellectual portfolio currently consists of nineteen patent families, including 31 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio. 
